Product Code: MDS051B
The global market for tissue diagnostics is estimated to increase from $8.9 billion in 2024 to reach $12.4 billion by 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 through 2029.
The reagents market for tissue diagnostics is estimated to increase from $6.6 billion in 2024 to reach $9.3 billion by 2029, at a CAGR of 6.9% from 2024 through 2029.
The instruments market for tissue diagnostics is estimated to increase from $2.2 billion in 2024 to reach $3.1 billion by 2029, at a CAGR of 7.0% from 2024 through 2029.
Report Scope
The report provides an analysis of the tissue diagnostics market, along with a competitive landscape and profiles of leading companies that include their revenues, product portfolios and recent activities. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services. Organizations, distributors and exporters should find useful information about market developments and trends.
The study segments the market on multiple bases. By product type, the market is segmented into instruments and reagents (reagents/test kits/consumables of tissue diagnostics).
By segment type, the market is divided into histopathology, which includes hematoxylin and eosin stains (H&E) and immunohistochemistry (IHC); molecular pathology, which includes in situ hybridization (ISH), polymerase chain reaction (PCR) and next-generation sequencing (NGS); microbiological testing, which includes general culture testing and antimicrobial susceptibility testing and identification (AST/ID); and digital pathology.
Regional market analysis is provided for all the major segments. The regions are North America; Europe; Asia-Pacific; Latin America; and Rest of the World (RoW), which in this report consists of the Middle East and Africa. The report also provides country-level analyses of markets and market segments.
The report covers only tissue sample-based tests. The liquid biopsy market; swab, saliva and urine-based tests; and the service testing market of tissue diagnostics are outside the scope of the report.
In this report, the tissue diagnostics market is segmented by:
Product type:
Segments:
- Histopathology (H&E, IHC).
- Molecular pathology (ISH, PCR and NGS).
- Microbiological testing (general culture testing, AST/ID testing) .
- Digital pathology.
Technology:
- H&E.
- IHC.
- ISH.
- PCR.
- NGS.
- Digital pathology.
Applications:
- Oncology.
- Tissue typing.
- Pathogen detection and AST.
End users:
- Professional laboratories.
- Emergency care units.
- Academic and research institutes.
Report Includes
- 40 data tables and 42 additional tables
- An analysis of the global market trends for tissue diagnostics, with market revenue data from 2022 to 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
- Estimates of the size and revenue prospects of the global market, along with a market share analysis by type of test, technology, application, end user and region
- Facts and figures pertaining to the market dynamics, technical advances, regulations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- An analysis of patents, emerging trends and developments in the industry
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and Illumina Inc.
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Market Overview and Definitions
- Immunohistochemistry (IHC)
- In Situ Hybridization
- Polymerase Chain Reaction
- Next-Generation Sequencing
- General Culture Testing
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Increasing Incidence of Cancer Cases
- Companion Diagnostics in Cancer Treatment
- Importance of Early Cancer Testing
- Raising Awareness of Early Signs of Cancer
- Aging Population
- Market Opportunities
- Enhancing Access
- Digital Pathology
- Partnerships
- Market Restraints
- Cost of Tissue Diagnostic Tests
- Competing Technologies
- Turnaround Time
- Market Challenges
- Lack of Skilled Professionals
- Complex Sample Preparation and Handling
Chapter 4 Emerging Technologies and Developments
- Overview
- Digital Pathology and AI Integration
- 3D Tissue Pathology and AI
- Fluorescent In Situ Sequencing
Chapter 5 Tissue Diagnostics Testing Market
- Segmentation Breakdown
- Market Breakdown
- Market Breakdown, by Product Type
- Market Breakdown, by Technology
- Market Breakdown, by Segment
- Histopathology Market
- Molecular Pathology Market
- Microbiology Testing Market
- Digital Pathology Market
- Market Breakdown, by Application
- Market Breakdown, by End User
- Geographic Breakdown
- Market Breakdown, by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest of the World
Chapter 6 Competitive Intelligence
- Industry Scenario
- Competitive Landscape
Chapter 7 Sustainability in the Market for Tissue Diagnostics: An ESG Perspective
- Introduction to ESG
- Environmental Performance
- Social Performance
- Governance Performance
- Concluding Remarks from BCC
Chapter 8 Appendix
- Research Methodology
- References
- Acronyms
- Company Profiles
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- BD
- BIOCARE MEDICAL LLC.
- BIOMERIEUX
- BIO-RAD LABORATORIES INC.
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE LTD.
- ILLUMINA INC.
- KONINKLIJKE PHILIPS N.V.
- MERCK KGAA
- MYRIAD GENETICS INC.
- QIAGEN
- THERMO FISHER SCIENTIFIC INC.
- ZYTOVISION GMBH